Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has released the pricing of its public offering. The offering consists of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof) along with warrants to purchase up to 3,333,333 additional shares of its common stock. According to the announcement, the combined offering price will be $6 per share (or common stock equivalent) and associated warrants. The company noted that in addition to the $6 per share exercise price, the warrants will be immediately exercisable with an expiration date five years following the date of issuance. Aditxt anticipates the offering to close on or about Sept. 20, 2022, with H.C. Wainwright & Co. acting as exclusive placement agent for the offering. Based on the pricing, expected gross proceeds from the offering should reach an estimated $20 million, which Aditxt plans to use for general corporate purposes, including R&D, capital expenditures, working capital and general and administrative expenses as well as potential acquisitions or investments.
To view the full press release, visit https://ibn.fm/ssmQx
About Aditxt Inc.
Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system. The company’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit www.Aditxt.com and www.AditxtScore.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork